Lamivudine Mylan

Lamivudine, the active ingredient in Lamivudine Mylan, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral tablet for oral use. It is indicated for the treatment of HIV infection and chronic hepatitis B in adults and pediatric patients, where it is prescribed as part of combination antiretroviral therapy or as monotherapy for hepatitis B, helping to suppress viral replication.

GNH USA supplies Lamivudine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including both public and private healthcare networks.

Lamivudine is used to treat viral infections that involve reverse transcriptase activity, primarily HIV and hepatitis B. - HIV infection: reduces viral load and slows disease progression as part of combination antiretroviral therapy. - Chronic hepatitis B: suppresses hepatitis B virus replication and improves liver function when used alone or with other antivirals. - HIV/HBV co‑infection: provides dual antiviral activity to manage both viruses concurrently.

Lamivudine may cause a range of adverse reactions, most of which are mild and reversible. Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Fatigue: general tiredness. Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance requiring immediate medical attention. - Hepatotoxicity: significant liver enzyme elevations or hepatitis. - Severe rash: including Stevens‑Johnson syndrome.

When prescribing lamivudine, clinicians should consider several precautionary measures to ensure safe use. - Renal function: adjust dose in patients with impaired kidney function. - Hepatic disease: monitor liver enzymes in patients with existing liver disease. - Pregnancy: evaluate risk‑benefit ratio before use in pregnant women. - Concomitant medications: review for potential drug interactions, especially with other antiretrovirals. - Adherence: emphasize importance of consistent dosing to prevent resistance. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Lamivudine can interact with other medicines, affecting its efficacy or safety. Major Interactions (Avoid): - Didanosine: concurrent use increases risk of pancreatitis. - Stavudine: combined use may enhance mitochondrial toxicity. Moderate Interactions (Monitor Closely): - Tenofovir: may require renal function monitoring. - Efavirenz: may affect lamivudine plasma levels. - Rifampicin: can reduce lamivudine concentrations.